<DOC>
	<DOCNO>NCT00731380</DOCNO>
	<brief_summary>The purpose study determine high dose ABI-007 give cisplatin 5-fluorouracil without cause intolerable side effect patient advanced head neck cancer .</brief_summary>
	<brief_title>A Phase I Trial Abraxane , Cisplatin 5-Fluorouracil Along With Chemoradiotherapy Advanced Head Neck Cancer</brief_title>
	<detailed_description>Squamous cell carcinoma head neck ( HNSCC ) 9th common malignancy diagnose Canadians . In year 2007 , estimate 4,350 new case diagnose Canada , approximately 1,600 death attributable HNSCC [ Canadian Cancer Statistics 2007 ] . In United States annual incidence approximately 40,000 newly diagnose case head neck cancer [ US Cancer Statistics 2006 ] . Primary treatment newly diagnose localize ( stage I-II ) HNSCC surgery and/or radiotherapy . The majority patient ( 70 % ) however present locally advanced HNSCC ( Stage III IV ) . Treatment locally advance HNSCC generally consist either concurrent chemotherapy radiation surgical resection follow adjuvant radiation adjuvant concurrent chemotherapy radiation . Unfortunately despite aggressive treatment combine modality therapy approximately 40-50 % case recur , majority recur primary site and/or regional node . Except small minority patient salvage surgery radiotherapy deliver , prognosis majority patient poor treatment generally consider palliative .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Previously untreated squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx . Histological cytological confirmation require . The disease must consider potentially curable combine chemoradiation . Patients nasopharynx , paranasal sinus , skin unknown primary site eligible . 2 . Nonmetastatic , stage III IV disease ( UICC/AJCC classification , 6th edition ) 3 . Age ≥ 18 . 4 . ECOG performance status 0 1 . 5 . Patients must adequate hematological function : absolute granulocyte count &gt; 1.5 x 109/L platelet count &gt; 100 x 109/L hemoglobin &gt; 90 g/L 6 . Must adequate renal hepatic function : serum bilirubin &lt; 1.5x UNL AST/ALT &lt; 2.5x UNL serum creatinine &lt; 1.25 x UNL calculate creatinine clearance &gt; 60 ml/min 7 . Signed write consent . 8 . Availability followup treatment . 9 . The patient fertile aware risk become pregnant father child use adequate contraception ( oral contraception , IUD , diaphragm spermicide male condom spermicide ) throughout therapy least 3 month therapy . 10 . Life expectancy great 6 month 1 . Significant intercurrent illness interfere chemotherapy radiation therapy trial HIV infection , cardiac insufficiency , pulmonary compromise , active significant alcohol abuse , uncontrolled psychotic disorder , active infection febrile illness . 2 . Any history myocardial infarction , history ventricular arrhythmia , angina active coronary heart disease within 6 month . Significant cardiac disease result inability tolerate intravenous fluid load require administration cisplatin . 3 . Evidence distant metastasis . 4 . Symptomatic peripheral neuropathy ≥ grade 1 CTCAE v.3 criterion . 5 . Clinically significant sensorineural hearing impairment may exacerbate cisplatin ( audiometric abnormality without correspond clinical deafness ground exclusion ) 6 . Weight loss great 20 % usual body weight 3 month precede trial entry . 7 . High risk poor compliance therapy followup assess investigator . 8 . Pregnant lactating woman . 9 . Prior radiation therapy great 30 % bone marrow 10 . Prior experimental therapy cancer within 30 day enter trial . 11 . Prior radiation head neck cancer . 12 . Prior systemic chemotherapy cancer . 13 . Patients prior cancer , except : diagnosed five year ago evidence disease recurrence clinical expectation recurrence le 5 % ; successfully treat nonmelanoma skin cancer ; carcinoma situ cervix . However , patient previous invasive breast cancer , prostate cancer melanoma exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Abraxane</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Determine</keyword>
	<keyword>Maximum</keyword>
	<keyword>Tolerated dose</keyword>
	<keyword>ABI-007</keyword>
	<keyword>Combination</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>5-Fluorouracil</keyword>
	<keyword>Patients</keyword>
</DOC>